Interchangeable Biosimilars: Key Points for Patients

INTRODUCTION:

In these animated video
segments, Dr Jonathan Kay,
clinical expert in biosimilars,
focuses on the interchangeablility
designation, including clinical and
patient care implications.

BEGIN SERIES
Jonathan Kay picture

Jonathan Kay, MD
UMass Memorial Health
Worcester, MA

Ā©2022 Boehringer Ingelheim Inc. All Rights Reserved. SC-US-74798 11/22